Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that top-ranked analyst David Steinberg has been appointed as chief financial officer. He will be responsible for overseeing Prolacta's financial operations, including financial planning, reporting, accounting, business development, and investor relations.

Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team. As one of the first analysts to introduce specialty pharmaceuticals to Wall Street as a major growth opportunity about 25 years ago, Steinberg has a long list of accolades.

He has been regularly voted by portfolio managers to the Institutional Investor "All America Research Team." Most recently, he was ranked No. 2 in the sector for 2021 and has been recognized as a top stock picker by surveys such as The Wall Street Journal's "Best on the Street." Steinberg was also known for detailed "deep dive" financial reports on such topics as orphan drugs, attention deficit hyperactivity disorder, thyroid eye disease, narcolepsy, Latam Pharma, and a multiyear series on mergers and acquisitions (M&A) titled "Who's Next?"

"David's extensive experience is well recognized and respected within the industry," said Scott Elster, CEO of Prolacta. "His deep knowledge of the biotechnology and pharmaceutical sectors is reflected in the tremendous success achieved by the teams he has led. David's financial leadership and foresight will be key to furthering Prolacta's mission of improving the health and lives of more critically ill, premature infants globally through human milk nutrition. We are fortunate to have such a highly respected leader on our executive team."

Prior to joining Prolacta, Steinberg served as managing director for Jefferies and Deutsche Bank.